{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:39:23Z","timestamp":1791545963845,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107148","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:08:15Z","timestamp":1773763695000},"page":"107148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patients"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-8462","authenticated-orcid":false,"given":"Marco","family":"Puthenparampil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Basili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina A.","family":"Mauceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Nosadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107148_bib0001","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.0000000000002395","article-title":"CFSEP and OFSEP groups. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study","volume":"86","author":"Barbin","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107148_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-022-06211-8","article-title":"Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study","author":"Baroncini","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107148_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26913","article-title":"Determinants and biomarkers of progression independent of relapses in multiple sclerosis","author":"Calabrese","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2026.107148_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107148_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab229","article-title":"Relapse-independent multiple sclerosis progression under natalizumab","volume":"3","author":"Graf","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.msard.2026.107148_bib0007","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/acn3.52118","article-title":"A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis","volume":"11","author":"Iaffaldano","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107148_bib0008","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Coles A; MSBase Study Group. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107148_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: From biological effects to immune monitoring","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107148_bib0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamaneurol.2013.923","article-title":"Natalizumab therapy for highly active pediatric multiple sclerosis","volume":"70","author":"Kornek","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2026.107148_bib0011","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107148_bib0012","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107148_bib0013","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2026.107148_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-023-00549-7","article-title":"No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: Clinician and patient perspectives [Narrative Review]","author":"Newsome","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2026.107148_bib0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028993","article-title":"Microglial phenotypes and functions in multiple sclerosis","volume":"8","author":"O\u2019Loughlin","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"15","key":"10.1016\/j.msard.2026.107148_bib0016","article-title":"Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score-matched study","author":"Pape","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107148_bib0017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00415-018-9117-z","article-title":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation","volume":"266","author":"Pfeuffer","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107148_bib0018","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A Randomized, Placebo-Controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107148_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awac111","article-title":"Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study","volume":"145","author":"Portaccio","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107148_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241266180","article-title":"Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context","author":"Prosperini","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107148_bib0021","first-page":"11","article-title":"NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis","author":"Puthenparampil","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107148_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1421755","article-title":"Hyper-reflective foci changes in RRMS under natalizumab therapy","volume":"15","author":"Puthenparampil","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107148_bib0023","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200303","article-title":"High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis","volume":"11","author":"Puthenparampil","year":"2024","journal-title":"Neurol. neuroimmunol. neuroinflamm."},{"key":"10.1016\/j.msard.2026.107148_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1475161","article-title":"A comparison of natalizumab\u2019s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients","volume":"15","author":"Puthenparampil","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107148_bib0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.msard.2026.107148_bib0026","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1007\/s00415-024-12638-0","article-title":"Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis","volume":"271","author":"Simone","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107148_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/j.1527-3458.2007.00003.x","article-title":"Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri\u00ae) in inflammatory diseases","author":"St\u00fcve","year":"2007","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.msard.2026.107148_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000574","article-title":"Natalizumab treatment reduces microglial activation in the white matter of the MS brain","volume":"6","author":"Sucksdorff","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107148_bib0029","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107148_bib0031","article-title":"A randomized study of natalizumab dosing regimens for relapsing\u2013remitting multiple sclerosis. Mult. Scler","volume":"27","author":"Trojano","year":"2021","journal-title":"J"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:20:15Z","timestamp":1781526015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"alternative-id":["S2211034826001847"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107148","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107148"}}